Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Research Abstract |
Suppression of BRAF expression in human anaplastic thyroid carcinoma cell line NPA, human papillary thyroid carcinoma cell line K1 those have BRAF mutation which is involved in malignant transformation and papillary thyroid carcinoma cell line TPC1 without BRAF mutation reduced expression of genes related to malignant transformation. In clinical thyroid carcinoma specimen, approximately 90% of cases have mutation in BRAF activating mutation. HSP90 inhibitor which is anticipated to reduce BRAF expression inhibits cell proliferation in other cancer cell lines.
|